ArticleJournal of materials science. Materials in medicine2014
The inhibition of lamellar hydroxyapatite and lamellar magnetic hydroxyapatite on the migration and adhesion of breast cancer cells.
Article in Journal of materials science. Materials in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 47 citations in OpenAlex.
- Synergistical Induction of Apoptosis via Cold Atmospheric Plasma and Nanohydroxyapatite for Selective Inhibition of Oral Squamous Cell Carcinoma in Tumour Microenvironment.Cell proliferation · 2025Article
- Biomaterial-assisted tumor therapy: A brief review of hydroxyapatite nanoparticles and its composites used in bone tumors therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Osteoporotic bone recovery by a bamboo-structured bioceramic with controlled release of hydroxyapatite nanoparticles.Bioactive materials · 2022Article
- Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer.International journal of molecular sciences · 2022Review
- Versatile-in-All-Trades: Multifunctional Boron-Doped Calcium-Deficient Hydroxyapatite Directs Immunomodulation and Regeneration.ACS biomaterials science & engineering · 2022Article
- Anti-melanoma effect and action mechanism of a novel chitosan-based composite hydrogel containing hydroxyapatite nanoparticles.Regenerative biomaterials · 2022Article
- Combination of Goniothalamin and Sol-Gel-Derived Bioactive Glass 45S5 Enhances Growth Inhibitory ActivityBioMed research international · 2022Article
- Rice field snail shell anticancer properties: An exploration opinion.Frontiers in oncology · 2022Article
- Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect.Science advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxyapatite nanoparticles have been reported to exhibit potent anti-tumor effects in some cancer cells. In our previous study, we have successfully synthesized two types of hydroxyapatite nanoparticles, laminated hydroxyapatite (L-HAp) and laminated magnetic hydroxyapatite (LM-HAp). In this study, we wanted to investigate the effects of L-HAp and LM-HAp with various concentrations on human breast cancer MDA-MB-231 cells. Cell proliferation was assessed with a MTT colorimetric assay. Scratch and adhesion assays were used to detect the effects of these two materials on migration and adhesion. The expressions of integrin β1 and Akt were measured by Western blotting. Our results showed that L-HAp and LM-HAp had little cell cytotoxicity and significantly reduced cell mobility and adhesion. LM-HAp showed greater inhibitor ability on migration and adhesion of MDA-MB-231 cells. Moreover, results from western blotting showed that L-HAp and LM-HAp impacted the phosphorylation of integrin β1, but showed no regular impact on Akt. This study suggests that L-HAp and LM-HAp may be potential anti-tumor and delivery system for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.